1. Pink Sheet

Clarifying "Clear, Conspicuous and Neutral": Advertisers Will Learn New DTC Standard on the Fly

 
• By Michael McCaughan

FDA's new pre-review program for direct-to-consumer ads is up and running. The agency also has a working definition for the new standard governing risk information in broadcast ads: present it the same way you do the benefits.

Michael McCaughan

As one of his duties resulting from the FDA Amendments Act, Division of Drug Marketing Advertising & Communications Director Tom Abrams needs to define "clear, conspicuous

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

EMA Explores Using AI Language Models To Refine Oncology Guidance

 
• By Vibha Sharma

The European Medicines Agency has for the first time explicitly stated it is considering the use of large language models as a tool to improve the readability of a scientific guideline.

Industry On Making England’s HTA Innovation Lab A Success

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.